Rescreen interval or d c of screening based on pt preference age PSA prostate CA risk life expectancy and general health following shared decision making CR AUA B 13

By rray, 2 August, 2024
Exclude Patient Type Detail Header
No
Detail Type
Text
Detail Text
Per ACP no evidence that screening more often than q4y offers additional benefit 12
Per ACS if PSA
Per NCCN if average risk w PSA
Per NCCN if normal DRE and high risk w PSA 3 or average risk w PSA 1 3 ng mL retest q1 2y 3
Consider annual screening for Black pts depending on PSA value and health status and esp for those w strong FHx or who carry high risk genetic variant 5
If very suspicious DRE and or PSA 3 ng mL bx indicated 3 Validated risk calculators may be used to inform shared decision making process for prostate bx CR AUA B 13
Patient Type Detail Header (Long)
<b>Rescreen interval</b> or d/c of screening based on pt preference, age, PSA, prostate CA risk, life expectancy, and general health, following shared decision-making [CR][AUA-B].<sup>13</sup>